An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor

Archives of Internal Medicine

Volumn 158, Issue 6, 1998, Pages 577-584

  Black, Donald M ^a,b   Bakker Arkema, Rebecca G ^a,b   Nawrochi, James W ^a,b  

^a PFIZER INC   (United States)

^b Parke Davis Pharmaceuticals

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ABDOMINAL PAIN; ADULT; AGED; CLINICAL TRIAL; CONSTIPATION; DEATH; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MYOPATHY; PRIORITY JOURNAL; REVIEW;

ACYL COENZYME A; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CREATINE KINASE; FEMALE; HEPTANOIC ACIDS; HUMANS; LIVER; MALE; MIDDLE AGED; MUSCLES; PYRROLES; TRANSAMINASES;

EID: 0032559785     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.6.577     Document Type: Review

References (60)

1. Ma PTS, Gil G, Sudhf TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA. 1986;83:8370-8374.
2. Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolemia. Atherosclerosis. 1996;119:203-213.
3. Kasim SE, LeBoeuf RC, Khilnani S, Tallapaka L, Dayananda D, Jen KL. Mechanisms of triglyceridelowering effect of HMG-CoA reductase inhibitor in a hypertriglyceridemic model, the Zucker obese rat. J Lipid Res. 1992;33:1-7.
4. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vase Biol. 1995;15:678-682.
5. Bakker-Arkema RG, Best J, Fayyad R, et al. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis. 1997;131:17-23.
6. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-133.
7. Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results, IV: additional perspectives on the tolerability of lovastatin. Am J Med. 1991;91 (suppl 1B):25S-30S.
8. Mantell G, Burke T, Staggers J. Extended clinical safety profile of lovastatin. Am J Cardiol. 1990; 66:11B-15B.
9. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
10. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: 2-year efficacy and safety followup Am J Cardiol. 1994;74:667-673.
11. Lovastatin Study Groups I-IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med. 1993; 153:1079-1087.
12. Hunninghake DB, Mellies MJ, Goldberg AC, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, II: once-daily versus twice-daily dosing. Atherosclerosis. 1990;85: 219-227.
13. Hunninghake DB, Knopp RH, Schonfeld G, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, I: a dose-response study. Atherosclerosis. 1990;85:81-89.
14. Hoogerbrugge N, Mol MJ, Van Dormaal JJ, et al. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. J Irtern Med. 1990;228:261-266.
15. Beigel Y, Brook G, Eisenberg S, et al. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience. Isr J Med Sci. 1993;2:272-277.
16. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med. 1993; 153:1321-1329.
17. Simons LA, Nestel PJ, Clifton P, Janus ED, Simons J, Parfitt A. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over 3 years. Med J Aust. 1992;157:584-589.
18. Simons LA. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. Clin Cardiol. 1993; 16:317-322.
19. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996;156: 2085-2092.
20. Emmerick J, Aubert I, Bauduceau B, et al. Efficacy and safety of Simvastatin (alone or in association with colestyramine): a 1-year study in 66 patients with type II hyperlipoproteinaemia. Eur Heart J. 1990;11:149-155.
21. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of Simvastatin in preparation for a large mortality study. Eur Heart J. 1994;15:255-269.
22. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and Simvastatin in patients with primary type lla or llb hyperlipidemia. Arch Intern Med. 1994; 154:441-449.
23. Molgaard J, Lundh BL, von Schenck H, Olsson AG. Long-term efficacy and safety of Simvastatin alone and in combination therapy in treatment of hypercholesterolaemia. Atherosclerosis. 1991;91 (suppl):S21-S28.
24. Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of Simvastatin. Am J Cardiol. 1991;68:1127-1131.
25. Stalenhoef AF, Lansberg PJ, Kroon AA, et al. Treatment of primary hypercholesterolaemia: short-term efficacy and safety of increasing doses of Simvastatin and pravastatin: a double-blind comparative study. J Intern Med. 1993;234:77-82.
26. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of Simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol. 1993;71:1408-1414.
27. Peters TK. Safety profile of fluvastatin. Br J Clin Pract Symp Suppl. 1996;77A:20-23.
28. Davidson MH. Fluvastatin Long-term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med. 1994;96(suppl 6A):41S-44S.
29. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hyperctiolesterolemia. Ann Pharmacother. 1995:29:743-759.
30. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety, Eur Heart J. 1995:16:5-13.
31. Walker JF, Tobert JA. The clinical efficacy and safety of lovastatin and MK-733: an overview. Eur Heart J. 1987;8(suppl E):93-96.
32. Bertolini S, Bittolo Bon G, Campbell LM, et al. The efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130:191-197.
33. Heinonen TM, Schrott JH, McKenney JM, et al. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Ther. 1996;1:117-122.
34. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, 1 -year study comparing the safety and efficacy of once-daily atorvastatin with that of simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997;80:39-44.
35. Heinonen TM, Stein E, Weiss SR, et al. The lipidlowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-blind study. Clin Ther. 1996;18:853-863.
36. Davidson M, McKenney J, Stein E, et al. Comparison of 1 -year efficacy and safety of atorvastatin-versus-lovastatin in primary hypercholesterol-emia: Atorvastatin Study Group I. Am J Cardiol. 1997;79:1475-1481.
37. Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxymethylglutarylcoenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997;17:1793-1799.
38. Heinonen TM, Schrott H, Broyles F, Shurzinske L, Black DM. An evaluation of estrogen and atorvasatin, a new HMGRI, in hypercholesterolemic postmenopausal women. Presented at the 66th Congress of the European Atherosclerosis Society; July 13, 1996; Florence, Italy.
39. Gmerek A, Yang R, Bays H, et al. Atorvastatin causes a dose-dependent reduction in LDL-C and triglycerides. Presented at the 66th Congress of the European Atherosclerosis Society; July 13, 1996; Florence, Italy.
40. Seiler K-U, Wolffenbuttel BHR, Mahla G, et al Comparison of atorvastatin, a new HMG-CoA reductase inhibitor, with pravastatin and simvastatin. Atherosclerosis. 1994;109(special issue):314.
41. Best JD, Nicholson GC, O'Neal DN, Kotowicz MA, Tebbutt NC, Chan K-W, Sanders KM. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diab Nutr Metab. 1996;9:74-80.
42. Reckless JPD, Stirling CA, Cole D, Sethi S, Williams C, Gould B. Influence of 2 hydroxymethylgluteryl coenzyme-A reductase inhibitors on postprandial lipoprotein and apo B-48 metabolism. Presented at the 66th Congress of the European Atherosclerosis Society; July 13, 1996; Florence, Italy.
43. McCormick L, Black D. A 12-week study comparing atorvastatin with niacin patients with hypertriglyceridemiawith or without hypercholesterolemia. Presented at the 66th Congress of the European Atherosclerosis Society; July 13,1996; Florence, Italy.
44. Nawrocki J, Schwartz S, Fayyad R, Simunovic L. Atorvastatin, a new HMG-CoA reductase inhibitor is safe and effective in NIDDM patients with hyperlipidemia. Presented at the 66th Congress of the European Atherosclerosis Society; July 13, 1996; Florence, Italy.
45. Heinonen T, Black D. Atorvasatin monotherapy and combination therapy in the treatment of severe hypercholesterolemia. Atherosclerosis. 1995;115 (suppl):S20.
46. Wagner B, Huwel D, Rehorst D, Smilde JG, Wunderlich J, Black D. A 1-year treat-to-target study of atorvastatin vs pravastatin in risk-stratified hypercholesterolemic patients. Presented at the 66th Congress of the European Atheroslcerosis Society; July 13,1996; Florence, Italy.
47. Marais AD, Firth JC, Bateman M, Byrnes P, Martens C, Mountney J. Atorvastatin: an effective lipidmodifying agent in familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol. 1997;17: 1527-1531.
48. Dujovne CA, Harris WS, Altman R, Overhiser RW, Cunningham JJ, Black DM. Changes in hemorheology and atherothrombotic parameters by improving serum lipids in atorvastatin. Presented at the 66th Congress of the European Atherosclerosis Society; July 13,1996; Florence, Italy.
49. Marais D, Naoumova RP, Firth JC, Penny C, Neuwirth CKY, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 1997;38:2071-2078.
50. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
51. National Diabetes Data Group. Classification and diagnosis of diabetes and other areas of glucose intolerance. Diabetes. 1979;28:139-157.
52. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 4th ed. Washington, DC: Food and Drug Administration, Dept of Hearth and Human Services; 1993.
53. Goldman J, Matz R, Mortimer R, Freeman R. High elevations of creatine phosphokinase in hypothyroidism: an isoenzyme analysis. JAMA. 1977;238: 325-326.
54. Ciaravino V, Kropko ML, Rothwell CE, Hovey CA, Theiss JC. The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia. Mutat Res. 1995;343:95-107.
55. 1996 Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Co; 1996:765-769, 1699-1703,1775-1779, 2267-2269.
56. Lipitor [package insert], Ann Arbor, Mich: Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co; 1997.
57. Ballare M, Campanini M, Catania E, Bordin G, Zaccala G, Monteverde A. Acute cholestatic hepatitis during simvastatin administration. Recenti Prog Med. 1991;82:233-235.
58. Tobert JA, Shear CL, Chremos AN, Mantell GE. Clinical experience with lovastatin. Am J Cardiol. 1990;65:23F-26F.
59. Jick H. Drug-associated asymptomatic elevations of transaminase in drug safety assessments. Pharmacotherapy. 1995;15:23-25.
60. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990; 264:71-75.